SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Life Scienc - Quaterly Results

20 Apr 2022 Evaluate
The revenue zoomed 10.04% to Rs. 5140.57 millions for the quarter ended March 2022 as compared to Rs. 4671.63 millions during the corresponding quarter last year.The Net proft of the company remain more or less same to Rs. 988.97  millions from Rs. 1046.84 millions ,decline by -5.53%.Operating Profit reported a sharp decline to 1473.06 millions from 1702.26 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 5140.57 4671.63 10.04 21232.14 18851.65 12.63 21232.14 18851.65 12.63
Other Income 50.95 3.41 1394.13 147.04 8.11 1713.07 147.04 8.11 1713.07
PBIDT 1473.06 1702.26 -13.46 6307.64 5918.85 6.57 6307.64 5918.85 6.57
Interest 1.25 211.78 -99.41 279.62 875.47 -68.06 279.62 875.47 -68.06
PBDT 1471.81 1490.48 -1.25 6028.02 5043.38 19.52 6028.02 5043.38 19.52
Depreciation 95.54 84.26 13.39 378.77 333.94 13.42 378.77 333.94 13.42
PBT 1376.27 1406.22 -2.13 5649.25 4709.44 19.96 5649.25 4709.44 19.96
TAX 387.30 359.38 7.77 1462.01 1193.63 22.48 1462.01 1193.63 22.48
Deferred Tax 18.25 11.94 52.85 85.74 66.17 29.58 85.74 66.17 29.58
PAT 988.97 1046.84 -5.53 4187.24 3515.81 19.10 4187.24 3515.81 19.10
Equity 245.05 19.60 1150.26 245.05 19.60 1150.26 245.05 19.60 1150.26
PBIDTM(%) 28.66 36.44 -21.36 29.71 31.40 -5.38 29.71 31.40 -5.38

Alivus Life Sciences Share Price

1066.65 -6.50 (-0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×